Rhesus (Rh) 
Introduction
Alloimmunization in most obstetric cases occurs after transplacental passage of fetal blood into the maternal system during pregnancy-related causes or events. Rarely can it occur following RhD mismatched blood transfusion.
The incidence of mismatched transfusion is quoted to be approximately 1 in 100,000 US population. In 2008, a total of 165 incompatible blood transfusions were reported in the United States community hospitals. 1 Prevention of alloimmunization in women of reproductive age is of utmost importance to avoid future pregnancy complications.
In cases of RhD mismatched blood transfusion, the suggested treatments include red blood cell exchange transfusion and administration of intravenous (IV) rhesus immune globulin (RhIg) within 72 hours. Described here is a case of RhD mismatched transfusion and treatment with only intravenous rhesus immune globulin (WinRho SD, NABI, Boca Raton, FL). The treatment was associated with significant, but transient elevations in Rh anti D antibody titers.
Case Report
An 18-year-old nulligravid woman was involved in a high-speed motor vehicle accident and was found to be unstable with a blood pressure of 76/38 mm Hg. The initial work-up revealed extensive internal injuries and several fractures, as well as a small subdural hematoma. The patient emergently received four units of RhD positive blood. Following the transfusion, it was realized that the patient was RhD negative.
The implications of RhD incompatibility for future pregnancies were discussed with the patient. Intramuscular (IM) RhIg was determined to be impractical because of the large volumes needed. The option of red blood cell exchange transfusion was considered, though with a delay, due to concerns of increasing the intracranial pressure in the presence of a subdural hematoma. The patient and her family decided against the exchange transfusion for fear of complications. Due to the critical condition of the patient, the obstetrical team was consulted only fourteen days after admission regarding the implications of RhD sensitization in a woman of reproductive age group. The patient was counseled about obstetrical risks associated with RhD alloimmunization, and was offered treatment with intravenous (IV) RhIg. She decided in favor of this treatment.
The dose of RhIg was calculated based on the amount of RhD mismatched blood transfused.
The patient had received 1200 cc of blood. With a 55% hematocrit, that is equivalent to an exposure of 660 ccs of Rh positive red blood cells. The total dose of IV RhIg (dosed at 90 IU of IV RhIg per 1 mL of mismatched PRBCs) was calculated at 59,400 IU for our patient. Since the maximum daily dose of the IV RhIg advised is 3000 IU every 8 hours, we gave the total dose over a seven day period to ensure adequate treatment. RhD antibody titers were obtained daily during this treatment, and repeated monthly after discharge. The patient tolerated the treatment well and did not show any signs of overt jaundice or renal complications, and did not require any blood transfusion. The anti RhD antibody titers rose to a peak of 1:512, dropping to 1:8 at the end of the 3rd month. Even with the high RhD antibody titers, serum bilirubin levels remained below 2mg/ dl. [ Figure 1 ] Follow up titers were not available after the 3rd month.
Discussion
The reported rate of mismatched blood transfusion is approximately 1 per 12,000 units 2 and the complications of which are multiple. Factors such as amount of mismatched blood received and immune status contribute to the likelihood of RhD alloimmunization, which is approximately 80% after transfusion with 500 cc of RhD mismatched blood. 3 After the first exposure to RhD antigen, antibodies may not be detectable for at least 4 weeks.
In a mismatched blood transfusion, a red blood cell exchange transfusion or RhIg injection has been used successfully for prevention of RhD sensitization. The mechanism by which the RhIg inhibits sensitization is hypothesized to be by antigen clearance or by alteration of antigen processing and presenting. 
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When the volume of the inappropriate blood transfused is large, a combination of exchange transfusion and IV RhIg has been proposed. 6 Nester, et al described two cases where RhD negative women received RhD positive blood and were successfully treated with the combination therapy. 6 Both women had negative RhD antibody titers six months after the treatment.
Usage of RhIg alone, has been reported with success as well as failure which is probably dependent on the dosing of the RhIg.
. 7, 8 Blood volume as low as 0.1 ml can lead to Rh sensitization. 9 Inadequacy in the dosing of the RhIg could lead to failure of prophylaxis. In our case, even though the volume of the inappropriate blood transfused was large, we decided in favor of IV RhIg monotherapy due to the 14 day delay in the treatment. The dose of IV RhIg administered was large and calculated to cover the large volume of the RhD mismatched transfused blood, but the patient tolerated the treatment well.
In the previously reported case of treatment failure with RhIg alone, the patient was given 1,650 μg RhIg, for a single unit of RhD inappropriate blood transfusion. 7 In that case the RhD antibody titers were reported to rise to: 1:8, 1:512, 1:512, and 1:64, on posttransfusion days 6, 70, 119, and 369 respectively.
The persistence of antibodies more than one year later was taken as evidence of treatment failure, by the authors. In our case, following treatment with IV RhIg, the antibody titers rose significantly but the rise did not persist. By post-transfusion day 91, the RhD antibody titers had fallen from 1:512 to 1:8. Though we feel reassured with the drop in the titers, we cannot categorically comment on the long-term success of the management since the patient was lost to follow up.
In RhD sensitized pregnancies, RhD antibody titer between 1:8 and 1:32 is defined as the critical titer, above which the RhD positive fetus is at a significant risk for fetal hydrops. 10 The peak titer achieved in our case was 1:512 following treatment with the IV RhIg, and the higher titers persisted over a period of 2 months. Though our patient was not pregnant, the elevation in the RhD antibody titers has implications in a pregnant woman carrying an RhD positive fetus.
In recent times, IV RhIg has also been used successfully in the treatment of immune thrombocytopenic purpura (ITP) during pregnancy, the exact mechanism of which is not well understood. 11, 12 RhIg demonstrates the ability to block the reticuloendothelial system from clearing antibody-coated cells, and to also modulate the immune system.
12
Management of conditions such as mismatched blood transfusion and ITP with large doses of RhIg can lead to RhD antibody titers rising beyond the critical levels and can be potentially harmful to the fetus if the patient is pregnant.
Conclusion
It appears that IV RhIg alone is a safe and potentially effective treatment for prevention of alloimmunization following RhD mismatched blood transfusion, even when the volume is large. In cases of RhD mismatched blood transfusions, if the treatment is delayed beyond 14 days, IV RhIg should still be considered as long as the patient has a
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negative pre-treatment RhD antibody titer. However, due to the sharp rise in the RhD antibody titers following treatment, caution should be exercised when considering IV RhIg for treatment in pregnant women.
